MedTrace Logo

IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)

NCT02232425 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2020-08-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effectiveness of IX-01 in men with lifelong premature ejaculation.

Conditions

  • Premature Ejaculation

Interventions

DRUG

IX-01

DRUG

Placebo

Sponsors & Collaborators

  • Carelon Research

    collaborator OTHER

  • Novotech (Australia) Pty Limited

    collaborator INDUSTRY

  • ICON plc

    collaborator INDUSTRY

  • PHT Corporation

    collaborator INDUSTRY

  • Ixchelsis Limited

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02232425 on ClinicalTrials.gov